China Tests a Gene-and-Drug Switch for Brain Circuits in Humans
A Chinese research team has completed what it describes as the world’s first clinical study in humans of chemogenetic neuromodulation — a technique that gives doctors a chemical switch for turning specific nerve circuits on or off. The work was published on November 5 in the New England Journal of Medicine, one of the most closely read medical journals in the world, according to a report in Science and Technology Daily.
The approach combines two pieces of biology that are usually kept apart. First, a gene is delivered into a chosen population of neurons so that those cells carry a specially designed receptor. Then a small molecule drug is given that binds only to that receptor, changing how the cells fire. Because the drug dose can be adjusted and stopped, the intensity of the treatment is not fixed at the moment of surgery.
That adjustability is the point the journal’s invited commentators seized on. In an editorial accompanying the paper, outside experts argued that pairing gene therapy with a small molecule lets the strength of treatment be tuned on demand — something other forms of gene therapy, which typically deliver a permanent change, cannot offer.
The study was a joint effort. It involved a team led by Professor Zhao Guoguang at Xuanwu Hospital, part of Capital Medical University in Beijing, and a team led by Professor Luo Minmin at the Beijing Institute of Brain and Brain-Inspired Intelligence, working with a Beijing-based biotechnology company, Jianda Jiuzhou. The hospital is known for epilepsy and functional neurosurgery, a natural setting for a first-in-human test of a circuit-level therapy.
Chemogenetics has been a workhorse of laboratory neuroscience for years. Researchers use it to silence or activate specific cell types in animals and watch what behaviour changes. Moving it into people has been slow, because it requires both a gene-delivery step and a drug that is safe enough for humans, and because the regulatory path for combining the two is not obvious.
The report stops short of claiming a cure for any condition. What it establishes is that the combination can be delivered and controlled in patients, and that the concept has cleared the bar of a leading clinical journal with independent commentary. Larger trials would be needed before the technique could be judged on how well it actually helps people.
For global readers, the significance is less about one hospital and more about a category. If nerve activity can be dialled rather than permanently rewritten, the technique could eventually sit alongside deep brain stimulation and surgical ablation as a third option for hard-to-treat neurological conditions — one that is reversible and adjustable, but that carries the long tail of any gene therapy.
The next things to watch are practical: how many patients the trial enrolled and how they fared over time, whether regulators in China and elsewhere open a formal pathway for combined gene-and-drug devices, and whether other groups can reproduce the control the Beijing teams report. A first-in-human result is a door opening, not a room full of answers.